Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, Venetoclax, and Bortezomib in Relapsed/Refractory DLBCL
NCT04285268Phase 2Withdrawn
- Sponsor
- Rutgers University
- Start
- May 2020
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, venetoclax, bortezomib in diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), high grade B-cell lymphoma (HGBCL), sponsored by Rutgers University. Planned start May 2020; status: withdrawn.
02
Drugs
rituximabvenetoclaxbortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT04285268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04285268.